Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ARMOUR Residential REIT, Inc. (ARR) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
ARMOUR Residential REIT, Inc.Trade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs ARMOUR Residential REIT, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.08 (market cap $29.60B), while ARMOUR Residential REIT, Inc. trades at $16.71 (market cap $2.07B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 14.3× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYARR
Market Cap
$29.60B$2.07B
Sector
HealthFinancials
52-Week High
$491.22$19.12
52-Week Low
$205.48$14.05
Enterprise Value
$27.56B
Dividend Yield
17.28%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.

The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.

ARMOUR Residential REIT, Inc.

ARMOUR Residential REIT (ARR) trades at $16.54, down 0.84% on the day, amid a bearish technical signal. The stock shows a low P/E of 3.78 and trades below book value (P/B 0.91), suggesting potential undervaluation. Recent earnings were mixed, with a Q2 2026 beat but a Q4 2025 miss. The company maintains a high net income margin of 97.43% and consistent dividend payments, with the latest being $0.24 per share. Cash flow from operations improved to $319 million in 2026, though investing outflows remain high.

ARR presents a value opportunity with strong profitability and dividends, but faces risks from volatile earnings, high investing cash outflows, and a bearish technical outlook. Analyst sentiment is mixed, with 60% hold ratings. The stock's appeal hinges on sustained dividend payments and earnings stability amid interest rate sensitivity.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About ARMOUR Residential REIT, Inc.

ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.

Read more on ARR